BeyondSpring Inc. (BYSI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BeyondSpring Inc. (BYSI) trades at $1.70 with AI Score 29/100 (Grade F). BeyondSpring Inc. Market cap: $69.90M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for BYSI: BYSI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BYSI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BYSI: 1/1 perspectives are bearish.
How is this calculated? →BeyondSpring Inc. (BYSI) Healthcare & Pipeline Overview
BeyondSpring Inc. is a clinical-stage biopharmaceutical firm specializing in cancer therapies, primarily focused on Plinabulin, a selective immune-modulating microtubule-binding agent. The company targets chemotherapy-induced neutropenia and non-small cell lung cancer, differentiating itself through combination therapies and preclinical immune agents within the competitive biotechnology sector.
What Is the Investment Thesis for BYSI?
BeyondSpring Inc. presents a compelling investment thesis centered on the potential of Plinabulin, its lead asset, to address significant unmet needs in cancer therapy and supportive care. The successful completion of Phase III clinical trials for Plinabulin in CIN and NSCLC provides a foundation for potential regulatory approvals and commercialization. Key value drivers include the expansion of Plinabulin's applications through combination therapies with immuno-oncology agents, targeting a broader range of cancer indications. The company's preclinical pipeline of small molecule immune agents offers long-term growth potential. Upcoming regulatory decisions regarding Plinabulin's approval for CIN and NSCLC represent significant catalysts. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.
Based on FMP financials and quantitative analysis
BYSI Key Highlights
- Plinabulin has completed Phase III clinical trials for chemotherapy-induced neutropenia (CIN), demonstrating potential for regulatory approval and commercialization.
- The company is developing Plinabulin in combination with immuno-oncology agents, including nivolumab, to enhance efficacy in NSCLC and SCLC.
- BeyondSpring has three small molecule immune agents in preclinical stages, indicating a commitment to long-term innovation and pipeline expansion.
- The company's strategic focus on immune modulation and targeted therapies aligns with current trends in cancer research and treatment.
- Lan Huang leads the company as CEO, bringing experience in the biopharmaceutical industry to guide strategic direction and development.
Who Are BYSI's Competitors?
BYSI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| ARRY Array Technologies, Inc. | $6.94 | -0.37% | $1.07B | — |
| AGEN Agenus Inc. | $3.50 | +0.29% | $145.75M | — |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BYSI's Key Strengths?
- Promising lead asset, Plinabulin, with Phase III clinical trial data.
- Focus on immune modulation, a key area in cancer therapy.
- Pipeline of preclinical small molecule immune agents.
- Experienced management team.
What Are BYSI's Weaknesses?
- Clinical-stage company with no currently approved products.
- Reliance on the success of Plinabulin.
- Limited financial resources compared to larger pharmaceutical companies.
- High risk of clinical trial failures.
What Could Drive BYSI Stock Higher?
- Potential regulatory approval of Plinabulin for chemotherapy-induced neutropenia (CIN).
- Data readout from ongoing clinical trials of Plinabulin in combination with immuno-oncology agents.
- Advancement of preclinical small molecule immune agents into clinical development.
- Expansion of Plinabulin into new cancer indications through clinical trials.
- Formation of strategic partnerships and collaborations.
What Are the Key Risks for BYSI?
- Financial-distress signal — its Altman Z-Score of -31.68 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Plinabulin or other drug candidates.
- Regulatory delays or rejection of Plinabulin's approval.
- Competition from established pharmaceutical companies and other biotechnology firms.
- Patent expiration and generic competition.
- Difficulty in raising capital to fund ongoing research and development.
What Are the Growth Opportunities for BYSI?
- Expansion of Plinabulin into Combination Therapies: The market for combination therapies in oncology is rapidly expanding, driven by the need for more effective and personalized treatment approaches. BeyondSpring's development of Plinabulin in combination with immuno-oncology agents like nivolumab presents a significant growth opportunity. The global market for immuno-oncology is projected to reach $75 billion by 2028, providing a substantial addressable market for Plinabulin-based combination therapies. This strategy could enhance efficacy and broaden the therapeutic applications of Plinabulin, offering a competitive advantage.
- Regulatory Approval and Commercialization of Plinabulin for CIN: Chemotherapy-induced neutropenia (CIN) is a common and serious side effect of cancer treatment, affecting a significant portion of patients undergoing chemotherapy. The successful regulatory approval and commercialization of Plinabulin for CIN would address a critical unmet need and generate substantial revenue. The market for CIN treatments is estimated at $2 billion annually. Securing regulatory approval in major markets, such as the United States and Europe, is a key growth driver for BeyondSpring.
- Development of Preclinical Small Molecule Immune Agents: BeyondSpring's pipeline of three small molecule immune agents in preclinical stages represents a long-term growth opportunity. These agents target novel immune pathways and have the potential to address a wide range of cancers. While still in early stages of development, successful advancement of these programs could lead to breakthrough therapies and significant value creation. The company's drug development platform supports the identification and optimization of these novel candidates.
- Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with other pharmaceutical and biotechnology companies can accelerate the development and commercialization of BeyondSpring's therapies. Collaborations can provide access to complementary technologies, expertise, and resources. For example, partnering with a company specializing in drug delivery could enhance the bioavailability and efficacy of Plinabulin. Strategic alliances can also expand the company's reach into new markets and indications.
- Expansion into New Cancer Indications: BeyondSpring can expand its market reach by exploring Plinabulin's potential in other cancer indications beyond NSCLC and SCLC. This could involve conducting clinical trials in different types of solid tumors or hematological malignancies. The company's research and development efforts can focus on identifying new patient populations that could benefit from Plinabulin's immune-modulating properties. Expanding into new indications would diversify the company's revenue streams and reduce its reliance on specific cancer types.
What Opportunities Does BYSI Have?
- Regulatory approval and commercialization of Plinabulin.
- Expansion into new cancer indications.
- Strategic partnerships and collaborations.
- Advancement of preclinical programs into clinical development.
What Threats Does BYSI Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Clinical trial failures.
- Patent expiration and generic competition.
What Are BYSI's Competitive Advantages?
- Proprietary drug development platform.
- Patent protection for Plinabulin and other drug candidates.
- Clinical trial data demonstrating efficacy and safety.
- Expertise in immune modulation and cancer biology.
What Does BYSI Do?
Founded in 2010 and headquartered in New York, BeyondSpring Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. The company's primary focus is on Plinabulin, a selective immune-modulating microtubule-binding agent. Plinabulin has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia (CIN) and for the treatment of later-stage non-small cell lung cancer (NSCLC). This positions BeyondSpring as a key player in addressing critical unmet needs in cancer treatment and supportive care. BeyondSpring is also actively developing Plinabulin in combination with various immuno-oncology agents. These combinations include Plinabulin with nivolumab, a PD-1 antibody, for NSCLC treatment; Plinabulin with nivolumab and ipilimumab, a CTLA-4 antibody, for small cell lung cancer (SCLC); and Plinabulin in combination with PD-1 or PD-L1 antibodies and radiation for various cancers. These combination strategies aim to enhance the efficacy of existing immunotherapies and expand the therapeutic potential of Plinabulin. In addition to Plinabulin, BeyondSpring is engaged in the development of three small molecule immune agents in preclinical stages. These early-stage programs represent the company's commitment to long-term innovation and pipeline expansion. The company also utilizes a proprietary drug development platform to identify and advance novel therapeutic candidates. BeyondSpring's strategic focus on immune modulation and targeted therapies underscores its dedication to improving outcomes for cancer patients.
What Products and Services Does BYSI Offer?
- Develop cancer therapies focused on immune modulation.
- Advance Plinabulin, a selective immune-modulating microtubule-binding agent.
- Conduct Phase III clinical trials for Plinabulin in chemotherapy-induced neutropenia (CIN).
- Develop Plinabulin in combination with immuno-oncology agents for NSCLC and SCLC.
- Develop three small molecule immune agents in preclinical stages.
- Utilize a proprietary drug development platform for novel therapeutic candidates.
- Target unmet needs in cancer treatment and supportive care.
How Does BYSI Make Money?
- Develop and commercialize cancer therapies.
- Generate revenue through the sale of approved drugs.
- Collaborate with other pharmaceutical companies for research and development.
- License intellectual property to generate additional revenue.
What Industry Does BYSI Operate In?
BeyondSpring Inc. operates within the competitive biotechnology industry, which is characterized by rapid innovation, high regulatory scrutiny, and significant investment in research and development. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. The company's focus on immune-modulating agents aligns with the broader industry trend towards immunotherapy and targeted treatments. BeyondSpring faces competition from established pharmaceutical companies and other biotechnology firms developing similar therapies. Success in this industry requires strong scientific expertise, effective clinical trial execution, and successful navigation of regulatory approval processes.
Who Are BYSI's Key Customers?
- Cancer patients undergoing chemotherapy.
- Oncologists and healthcare providers.
- Hospitals and cancer treatment centers.
- Pharmaceutical distributors and wholesalers.
FY2026 estForward Outlook
Wall Street analysts project BeyondSpring Inc. revenue of about $194.6M for fiscal 2026, with EPS near $1.98.
BYSI Valuation & Market Position
With a $69.90M market cap, BeyondSpring Inc. sits in the micro-cap segment of the market. Relative to its peer group, BYSI's quantitative score of 29/100 is below the peer average of 70/100.
ROE 24%Key Financial Metrics
Return on equity for BeyondSpring Inc. stands at 23.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -41.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -26.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.6%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
BeyondSpring Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -31.68 places it in the distress zone, a signal of elevated financial risk.
Company Profile
BeyondSpring Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Florham Park, United States.
BYSI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that management believes in the value of their stock.
- Community sentiment has shifted positively, with discussions highlighting potential breakthroughs in their drug development pipeline.
- Analysts have noted increased interest in BeyondSpring's innovative approach to cancer treatments, attracting attention from larger investors.
- The company's strategic partnerships have strengthened its market position, enhancing credibility and potential for growth.
Bear Case
- Concerns over the slow progress in clinical trials have dampened investor enthusiasm, leading to skepticism about timely product launches.
- Social sentiment has shown volatility, with some community members expressing doubts about the sustainability of recent gains.
- Recent market developments, including increased competition in the oncology sector, have raised red flags among potential investors.
- There are lingering questions about the company's financial health, with some analysts pointing to the need for additional funding to support ongoing projects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BYSI Latest News
-
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga · May 13, 2026
BYSI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BYSI.
Price Targets
Wall Street price target analysis for BYSI.
BYSI MoonshotScore
What does this score mean?
The MoonshotScore rates BYSI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lan Huang
CEO
Lan Huang is the CEO of BeyondSpring Inc. She has extensive experience in the biopharmaceutical industry, with a background in drug development and commercialization. Prior to joining BeyondSpring, she held leadership positions at several pharmaceutical companies, where she was responsible for overseeing clinical trials, regulatory submissions, and product launches. Her expertise spans various therapeutic areas, including oncology and immunology. She has a proven track record of successfully bringing new drugs to market and building successful biopharmaceutical companies.
Track Record: Under Lan Huang's leadership, BeyondSpring has made significant progress in advancing Plinabulin through clinical development. She has overseen the completion of Phase III clinical trials for Plinabulin in chemotherapy-induced neutropenia and non-small cell lung cancer. Her strategic decisions have focused on expanding Plinabulin's applications through combination therapies and building a pipeline of preclinical small molecule immune agents. She manages 40 employees.
What Investors Ask About BeyondSpring Inc. (BYSI) — Healthcare
What does BeyondSpring Inc. do?
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. Its lead asset, Plinabulin, is a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia (CIN) and for the treatment of later-stage non-small cell lung cancer (NSCLC). The company is also developing Plinabulin in combination with various immuno-oncology agents and has a pipeline of preclinical small molecule immune agents. BeyondSpring aims to address unmet needs in cancer treatment and supportive care through its innovative therapies.
What do analysts say about BYSI stock?
Analyst coverage of BeyondSpring Inc. focuses on the potential of Plinabulin to address significant unmet needs in cancer therapy and supportive care. Key valuation metrics include the potential market size for Plinabulin in CIN and NSCLC, as well as the company's pipeline of preclinical assets. Growth considerations include the successful regulatory approval and commercialization of Plinabulin, as well as the advancement of its combination therapy programs. Analyst ratings and price targets reflect expectations for the company's future performance based on these factors. However, these are just opinions and should not be taken as financial advice.
What are the main risks for BYSI?
The main risks for BeyondSpring Inc. include the potential for clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's reliance on Plinabulin as its lead asset also poses a risk, as any setbacks in its development or commercialization could significantly impact the company's prospects. Additionally, the biotechnology industry is subject to rapid technological advancements and changing regulatory landscapes, which could create challenges for BeyondSpring. Securing adequate funding for ongoing research and development is also a critical risk factor.
What are the key factors to evaluate for BYSI?
BeyondSpring Inc. (BYSI) holds an AI score of 29/100 (low). Not financial advice.
How frequently does BYSI data refresh on this page?
BYSI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BYSI's recent stock price performance?
BeyondSpring Inc. (BYSI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Promising lead asset, Plinabulin, with Phase III clinical trial data. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BYSI overvalued or undervalued right now?
Valuing BeyondSpring Inc. (BYSI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BYSI?
Before investing in BeyondSpring Inc. (BYSI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-10.
- Future events and outcomes are subject to uncertainty and may differ from current expectations.